drugset / Trial / NCT01202175

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

NCT01202175

RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators aim to evaluate subjects at high risk of future development of hypertension, those with a family history of hypertension and/or that already have high normal(SBP 120-139 mmHg or DBP 80-89 mmHg) blood pressure. The investigators plan to investigate whether these subjects have the same markers (such as microscopic protein in the urine or C-reactive protein in the blood) in the blood and urine that people with high blood pressure have, and whether they are improved before and after taking the beta-blocker nebivolol.

Timeline

Start
2010-07
Primary completion
2012-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nebivolol Other / unclassified 2.5 mg Oral
Subject Nebivolol Other / unclassified 5 mg Oral

Indications